The first assay, a high-sensitivity troponin-I test, is planned launched in late 2021 with a heart failure marker, NT-pro-BNP, and other assays to follow. We welcome partnering initiatives from healthcare companies with attractive distribution networks both regionally and globally.
The SpinChip technology will bring added value to several methodology fields including hematologic methods (flowcytometry like), a variety of clinical chemistries, molecular diagnostics and companion diagnostics. Particularly sample processing including homogenisation, extraction and separation steps of e.g. tissue or faecal samples could be performed efficiently within a sealed cartridge. SpinChip is searching for competent partners to exploit these fields. Our present focus is on human in vitro diagnostics, but we also see a significant potential within veterinary diagnostics as well as other point of use analyses and advanced fluidic processing.
Please contact CEO Lars Halvor Langmoen (email@example.com) to explore partnership opportunities.